Skip to main content
Egyptian Liver Journal
Download PDF

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals

Egyptian Liver Journal volume 10, Article number: 41 (2020) Cite this article

Abstract

Background

Hepatitis C virus (HCV) infection is considered one of the main causes of chronic liver disease around the world. Liver biopsy has been believed to be the gold standard for the assessment of the degree of liver fibrosis. Thus, there is a need to improve non-invasive evaluation of liver fibrosis. The aim of the present study was to study the changes in serum levels of ATX (Autotaxin) as a marker of hepatic fibrosis in responders to HCV treatment by DAAs. This prospective study was carried out at hepatology outpatient clinics for HCV treatment in Mansoura Specialized Medical Hospital that involved 54 participants: 34 patients with HCV and 20 controls; ATX was measured for the controls and all patients before and after treatment.

Results

We found a significant higher ATX level in control subjects vs HCV patients, 100% of control subjects had ATX > 97.5 and 58.8% of HCV had ATX ≤ 97.5. Also, a significantly higher ATX after treatment with DAAs as a whole was observed.

Conclusion

The authors concluded that ATX should be considered cautiously as a diagnostic marker for liver fibrosis in Egyptian patients with chronic hepatitis C infection. Although this study yielded negative results, this may be important to prevent duplication of the research efforts.

Background

Hepatitis C virus (HCV) infection is considered one of the main causes of chronic liver diseases around the world. Around the world, there are about 71 million chronically infected persons [1].

Liver biopsy has been believed to be the gold standard for the assessment of the degree of liver fibrosis [2]. Diagnosis of liver fibrosis is commonly built on histological results after liver biopsy. The strategy of using biopsy to stage most cases of liver diseases has many restrictions such as sampling errors [1, 3], intraobserver, and interobserver variation during histological evaluation and hepatic biopsy is an invasive method with accompanied morbidity [3]. Due to these restrictions, the thought of liver biopsy as the “gold standard” has come down to “best available” standard [4].

Autotaxin (ATX) is a member of the ectonucleotidepyrophosphatase/phosphodiesterase (ENPP) family and considered a secreted glycoprotein [5]. It converts lysophosphatidylcholine (LPC) to the bioactive phospholipid lysophosphatidic acid (LPA) which is a multifunctional bioactive lipid mediator [6]. ATX is a necessary enzyme, which is required for early embryological development [7]. Serum ATX levels may increase during pregnancy [8] and in patients with idiopathic pulmonary fibrosis or some types of cancers [9,10,11]. In the serum, ATX is found and its metabolism is done by hepatic sinusoidal endothelial cells. Liver fibrosis inhibits metabolism of ATX, resulting in elevation of its serum levels. Due to these findings, ATX may be directly related to liver fibrosis [12].

Serum ATX was correlated to staging of liver fibrosis in patients with chronic hepatitis C (CHC). After comparison with serum hyaluronate and (APRI score), i.e., two confirmed markers for liver fibrosis [13], it was found that serum ATX level was the best parameter for predicting cirrhosis in both men and women [14].

This work aimed to study the changes in serum ATX levels as a sign of fibrosis of liver in responders to HCV treatment by DAAs.

Methods

Study design

The present study was prospective in nature and our patients were selected from the hepatology outpatient clinics for HCV treatment in Mansoura Specialized Medical Hospital.

Sample and selection of patients

From 34 patients and 20 controls serum samples have been obtained just before treatment (baseline), and at end of 12 weeks course of treatment for all patients. At – 20 °C until testing, all collected samples have been quickly stored, serum ATX has been measured using Human ENPP-2/ATX Quantikine ELISA Kit (manufactured and distributed by R&D systems, Inc., USA and Canada) according to the recommendations of the manufacturer.

Patients have been followed by investigations just before and 12 weeks after DAAs treatment to determine impact of DAAs on serum ATX levels and its correlation with fibrosis changes. DAAs regimen includes the 12 weeks course of Sofosbuvir and Daclatasvir ± Ribavirin. The goal of treatment is undetectable HCV RNA in plasma or serum by a sensitive assay (lower limit of detection ≤ 15 IU/ml) 12 weeks (SVR12) or 24 weeks (SVR24) after the termination of therapy as EASL, 2018 [1].

For SVR patients, a sample size of 31 achieves 99% power to detect a mean of paired differences of 0.2 with an estimated standard deviation of differences of 0.2 and with a significance level (alpha) of 0.005 using a two-sided paired t test.

This study was approved by the ethical committee of Mansoura Faculty of Medicine and its university hospital.

  • Medical Research committee has submitted study protocol for approval with code number: MS. 18.09.301.

  • Confidentially and personal privacy have been respected in all levels of the study.

  • Collected data has not been used for any other purpose.

Inclusion criteria

All responders to HCV treatment by DAAs who are clinically and virologically improved (DAAs regimen includes the 12-weeks course of Sofosbuvir and Daclatasvir + Ribavirin) and for the controls included were free of chronic liver diseases who are matched for age and sex.

Exclusion criteria

  • Patients with history of cancers and other causes of liver disease.

  • Previous liver transplantation.

  • Patients co-infected with HIV or HBV.

  • Other organ failure (heart failure and renal failure).

Laboratory investigations

Fasting blood glucose, liver function tests:(AST, ALT, ALP, total bilirubin, direct bilirubin, total albumin), kidney function tests: (serum creatinine and urea), serum AFP, serum ATX, PT, INR, CBC, HCV Ab, and HBsAg.

Statistical analysis

Sample size was calculated using PASS software (Hintze, J.; 2011. PASS 11. NCSS, LLC. Kaysville, UT, USA. www.ncss.com).

Data were entered and analyzed using IBM-SPSS software (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY, USA: IBM Corp.)

Repeated-measures graph was created by GraphPad Prism software for Windows (version 6.01) (Tables 1, 2, 3, 4, 5, 6 and 7).

Table 1 ATX level regardless of sex in the 2 groups: it showed a statistically significant higher ATX level in control subjects vs HCV patients
Full size table
Table 2 ATX cut-off value to discriminate HCV from control: it showed that ATX ≤ 97.5 has 100% specificity in discriminating HCV and control but it is not sensitive
Full size table
Table 3 ATX cut-off distribution in HCV and control: it showed that 100% of control subjects had ATX > 97.5 and 58.8% of HCV had ATX ≤ 97.5; a difference which is statistically significant
Full size table
Table 4 ATX before and after DAAs treatment: it showed a statistically significant higher ATX after treatment with DAAs as a whole. By stratifying the cases according to sex, this statistical significance exists only in male patients but not female patients
Full size table
Table 5 Laboratory data before and after treatment: it showed a statistically significant improvement (decrease) in AST, ALT, and APRI score, but no statistically significant change in platelet count and FIB4 score
Full size table
Table 6 APRI and FIB4 scores before and after treatment: it showed a statistically significant improvement in APRI score (but not FIB4 score) after treatment with DAAs
Full size table
Table 7 Correlation between ATX and baseline parameters: it showed only a statistically significant correlation between ATX and sex. No correlation exists between ATX and other parameters
Full size table

Results

Discussion

The present study included 54 individuals and they were subdivided into groups:

  • HCV group included 34 patients with chronic HCV.

  • Control group included 20.

Our study showed a statistically significant higher ATX level in control subjects vs HCV patients as Yamazaki and his colleagues 2017 [15] who found that median ATX concentrations were essentially higher in patients than in healthy persons in contrast to Fujimori et al. 2018 [16] who found elevated serum/plasma ATX concentrations in hepatic patients.

Also, in accordance with our findings, Ezzat and his colleagues found elevated levels of serum autotaxin among controls higher than HCV patients (Ezzat et al. 2013 [17]).

That could be explained by the differences between populations according to molecular basis for serum ATX expression. There is contradiction in our findings because of liver bilharziasis among Egyptian patients with chronic HCV. There are different findings in our study due to genetic difference between the studied Egyptian patients and other foreign patients in previous studies. Serum ATX expression may be affected by different patterns of immune expression such as environmental stress, genetic predisposition, and bilharziasis (Ezzat et al. 2013 [17]).

In the present study, we found a statistically significantly higher ATX after treatment with DAAs as a whole.

We also found a statistically significant improvement in APRI score and non-statistically significant improvement in FIB4 score after treatment with DAAs.

In the present study, there was a statistically significant improvement (decrease) in AST, ALT after DAAs treatment as Khan and his colleagues 2017 [18] found that hepatic enzymes, frequently increased in chronic hepatitis C patients, tend to decrease to baseline during hepatitis C virus treatment.

Limitations

Not all patients agreed to be in a research and came for follow-up easily.

Conclusion

Overall, it can be concluded that ATX should be considered cautiously as a diagnostic marker for liver fibrosis in Egyptian patients with chronic hepatitis C infection. Although this study yielded negative results, this may be important to prevent duplication of the research efforts.

Recommendations

  • Larger sample sizes, longer study period and different ethnicities are necessary to confirm these findings.

  • That our promising results need further confirmation.

  • Liver biopsy is recommended as the gold standard method for determining fibrosis.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding on reasonable request.

Abbreviations

DAAs:

Direct-acting antivirals

APRI score:

(AST)-to-platelet ratio index

SVR:

Sustained virologic response

HIV:

Human immunodeficiency virus

HBV:

Hepatitis B virus

AST:

Aspartate aminotransferase

ALT:

Alanine aminotransferase

ALP:

Alkaline phosphatase

AFP:

Alpha-fetoprotein

PT:

Prothrombin time

INR:

International normalized ratio

CBC:

Complete blood count

HCV Ab:

Hepatitis C virus antibody

HBs Ag:

Hepatitis B surface antigen

IFN:

Interferon

FIB4:

Fibrosis index based on the 4 factors

References

  1. European Association for The Study of The Liver (2018) EASL recommendations on treatment of hepatitis C 2018. J Hepatol 69(2):461–511

    Article  Google Scholar 

  2. Bedossa P, Dargere D, Paradis V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 38:1449–1145

    Article  Google Scholar 

  3. Cadranel JF, Rufat P, Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 32:477–481

    Article  CAS  Google Scholar 

  4. Bedossa P, Carrat F (2009) Liver biopsy: the best, not the gold standard. J Hepatol 50(1):1–3

    Article  Google Scholar 

  5. Nakanaga K, Hama K, Aoki J (2010) Autotaxin--an LPA producing enzyme with diverse functions. J Biochem 148(1):13–24

    Article  CAS  Google Scholar 

  6. Ikeda H, Yatomi Y (2012) Autotaxin in liver fibrosis. Clin Chim Acta 413(23-24):1817–1821

    Article  CAS  Google Scholar 

  7. Koike S, Yutoh Y, Keino-Masu K et al (2011) Autotaxin is required for the cranial neural tube closure and establishment of the midbrain– hindbrain boundary during mouse development. DevDyn. 240(2):413–421

    Google Scholar 

  8. Masuda A, Fujii T, Iwasawa Y et al (2011) Serum Autotaxin measurements in pregnant women: application for the differentiation of normal pregnancy and pregnancy-induced hypertension. Clin Chim Acta 412:1944–1950

    Article  CAS  Google Scholar 

  9. Oikonomou N, Mouratis MA, Tzouvelekis A et al (2012) Pulmonary Autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 47:566–574

    Article  Google Scholar 

  10. Nakai Y, Ikeda H, Nakamura K et al (2011) Specific increase in serum Autotaxin activity in patients with pancreatic cancer. Clin Biochem 44:576–581

    Article  CAS  Google Scholar 

  11. Xu A, Ahsanul Kabir Khan M, Chen F et al (2016) Overexpression of Autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression. Med Oncol 33:131

    Article  Google Scholar 

  12. Yanase M, Ikeda H, Ogata N et al (2003) Functional diversity between Rho-kinase-and MLCK-mediated cytoskeletal actions in a myofibroblast-like hepatic stellate cell line. Biochem Biophys Res Commun 305(2):223–228

    Article  CAS  Google Scholar 

  13. Manning DS, Afdhal NH (2008) Diagnosis and quantitation of fibrosis. Gastroenterology 134:1670–1681

    Article  CAS  Google Scholar 

  14. Nakagawa H, Ikeda H, Nakamura K et al (2011) Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta 412:1201–1206

    Article  CAS  Google Scholar 

  15. Yamazaki T, Joshita S, Umemura et al (2017) Association of serum Autotaxin levels with liver fibrosis in patients with chronic hepatitis C. Sci Rep 7:46705

    Article  CAS  Google Scholar 

  16. Fujimori N, UmemuraT KT et al (2018) Serum Autotaxin levels are correlated with hepatic fibrosis and ballooning in patients with non-alcoholic fatty liver disease. World J Gastroenterol 24:1239–1249

    Article  CAS  Google Scholar 

  17. Ezzat WM, Ragab HM, El Maksoud NA et al (2013) Validity of Autotaxin as a Novel Diagnostic Marker for Liver Fibrosis in Egyptian Chronic HCV Patients. OA Maced J Med Sci 1(1):21–26

    Article  Google Scholar 

  18. Khan ST, McGuinty M, Corsi DJ et al (2017) Liver enzyme normalization predicts success of Hepatitis C oral direct acting antiviral treatment. Clin Invest Med 40(2):E73–E80

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Much gratitude is paid to Ministry of Health and population and National committee for control of viral hepatitis for their great efforts and all persons who helped in this work.

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Internal Medicine Department, Hepatology & Gastroenterology Unit, Mansoura Specialized Medical Hospital, Mansoura University Faculty of Medicine, Mansoura, Egypt

    Nancy Abdel Fattah Ahmed & Ahmed Galal Deiab

  2. Clinical Pathology Department, Mansoura University Faculty of Medicine, Mansoura, Egypt

    Ahmad Shawki Mohammad Hasan

  3. Master Second Candidate Internal Medicine, Sherbeen Hospital, Ministry of Health Dakahlia, Dakahlia, Egypt

    Ahmad Mohamed Yousry Abd Elbaky

Authors
  1. Nancy Abdel Fattah Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed Galal Deiab
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmad Shawki Mohammad Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmad Mohamed Yousry Abd Elbaky
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NAFA: manuscript review, design, manuscript editing, publishing, and final revision (CA). AGDA: idea of the study, data collection and follow-up. ASMH: laboratory studies. AMYA: literature search, clinical and statistics. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Nancy Abdel Fattah Ahmed.

Ethics declarations

Ethics approval and consent to participate

Study protocol was investigated and approved by the Medical Ethics Research Team, Faculty of Medicine, Mansoura University. Every case, after guaranteeing privacy, has given informed written consent (code number MS.18.09.301).

Consent for publication

Agreement of Ministry of Health and population and National committee for control of viral hepatitis.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, N.A.F., Deiab, A.G., Hasan, A.S.M. et al. Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals. Egypt Liver Journal 10, 41 (2020). https://doi.org/10.1186/s43066-020-00051-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s43066-020-00051-x

Keywords

  • Serum autotaxin
  • Direct-acting antivirals
  • Hepatic fibrosis